Obsidian Energy Ltd. is an exploration and production company. The firm engages in exploring, developing, and holds interests in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin directly and through investments in securities of subsidiaries holding such interests.
Take a look at the 1-year chart of Obsidian (NYSE: OBE) below with my added notations…
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product includes NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.
Take a look at the 1-year chart of Nkarta (NASDAQ: NKTX) below with the added notations…
MRC Global, Inc. is a holding company engaged in the distribution of pipes, valves, fittings, and other infrastructure products and services to the energy, industrial, and gas utility end-markets.
Take a look at the 1-year chart of MRC (NYSE: MRC) below with the added notations…
Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits.
Take a look at the 1-year chart of Lightwave (NASDAQ: LWLG) below with my added notations…
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel product development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
Take a look at the 1-year chart of Liquidia (NASDAQ: LQDA) below with added notations…